Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Toray Industries, Inc. (東レ株式会社 Tōre Kabushiki-gaisha) is a multinational corporation headquartered in Japan that specializes in industrial products centered on technologies in organic synthetic chemistry, polymer chemistry, and biochemistry.

Sidney Kimmel Cancer Center, a subsidiary of Sanford Burnham Prebys Medical Discovery Institute, is a company headquartered in San Diego, CA, that provides medical research services. It was acquired by Sanford Burnham Prebys Medical Discovery Institute on June 23, 2009 for $25 million.

Neovacs, a spin-off from the Pierre & Marie Curie University in Paris, was founded on 1993 by Professor Daniel Zagury, one of France's most eminent immunologists and AIDS experts. Neovacs holds a broad patent portfolio and is developing several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). At present, monoclonal antibodies are widely used to neutralize cytokines and treat patients suffering from cytokine-related diseases. In contrast to exogenous therapies with monoclonal antibodies, Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.

The BTG Specialty Pharmaceuticals business develops, manufactures and commercializes life-saving antidotes used in hospitals and emergency care settings, including the clinically proven and leading products CroFab®, DigiFab®, and Voraxaze®.

Gene Logic is a leading integrated genomics company providing comprehensive Genomic Reference Databases and GLP compliant Microarray Services. Over 2/3rd of the top 25 Pharma companies, leading research institutes and emerging biotech companies worldwide have chosen us as their preferred genomics partner and utilize our expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets & biomarkers.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. It operates through the following segments: Gene Editing Services, Pre-Clinical Pharmacology and Efficacy Evaluation, Animal Models Selling, Antibody Development, and Innovative Drugs Development. The Gene Editing Services segment provides gene editing services. The Pre-Clinical Pharmacology and Efficacy Evaluation segment involves in the provision of pre-clinical pharmacology service for drug efficacy and toxicity evaluation. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment includes one-stop solution from antibody preparation to IND filing for the customer. The Innovative Drugs Development consists of research and developing drugs with a focus on oncology and autoimmune disease therapeutics. The company was founded by Yue Lei Shen on November 13, 2009 and is headquartered in Beijing, China.

Biositu Jiangsu Gene Biotechnology Co., Ltd., established on 2014-10-14, Business scope includes licensed projects:Offshore trade operation;Experimental animal production;Experimental animal management(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology promotion and application services;Medical Research and Experimental Development;Technology Import and Export;Import and export agency;rental service(Licensed rental services not included);Non-residential real estate leases(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

The Jewish General Hospital (JGH; French: Hôpital général juif), known officially as the Sir Mortimer B. Davis Jewish General Hospital (French: Hôpital général juif Sir Mortimer B. Davis) since 1978, is an acute-care teaching hospital in Montreal, Quebec, Canada. Affiliated with McGill University, it has 637 beds.

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified, and lower-risk business than a typical biotech company. Ligand business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation, and partnering. Ligand partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management, and commercialization) to ultimately generate Ligand revenue.

Exostemtech Co., Ltd. is a company headquartered in Ansan-si, the South Korea. The firm operates as medical care company, which develops cell-free therapeutic systems. It was founded in 2016 by Yong-Woo Cho, he has been the CEO since then.

Transposagen Biopharmaceuticals is a privately held biotechnology company that is dedicated to providing unique animal models of human diseases for drug discovery and development. Transposagen is currently focusing on the $1.2 billion/year rodent model market. The rodent model market is experiencing double-digit annual growth due to the research and development needs of the pharmaceutical industry. It was founded in 2003 and is headquartered in Lexington, Kentucky.

Seegene, Inc. engages in the manufacturing and distributing of molecular diagnostics and reagents. Its diagnostic services include respiratory pathogen, gastrointestinal pathogen, sexually transmitted infections, human papillomavirus, tuberculosis, sepsis, meningitis, and pathogen. The company was founded by Jong-Yoon Chun on September 16, 2000 and is headquartered in Seoul, South Korea.

Commonwealth Scientific & Industrial Research Organisation provides scientific and industrial research services. It plays a role in collaboration within the Australian national innovation system and as an advisor to government, industry and the community. The company was founded in 1916 and is headquartered in Canberra, Australia.

Nanopharm Ltd. engages in the provision of orally inhaled and nasal drug product design and development services. It offers pre-formulation, formulation, and analytical solutions. The company was founded by Robert Price and is headquartered in Newport, the United Kingdom.